CA2901696C - Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer - Google Patents
Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer Download PDFInfo
- Publication number
- CA2901696C CA2901696C CA2901696A CA2901696A CA2901696C CA 2901696 C CA2901696 C CA 2901696C CA 2901696 A CA2901696 A CA 2901696A CA 2901696 A CA2901696 A CA 2901696A CA 2901696 C CA2901696 C CA 2901696C
- Authority
- CA
- Canada
- Prior art keywords
- oxo
- bis
- morpholinyl
- acid
- morpholinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361766625P | 2013-02-19 | 2013-02-19 | |
| US61/766,625 | 2013-02-19 | ||
| PCT/US2014/016971 WO2014130470A1 (en) | 2013-02-19 | 2014-02-18 | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2901696A1 CA2901696A1 (en) | 2014-08-28 |
| CA2901696C true CA2901696C (en) | 2021-04-13 |
Family
ID=50236309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2901696A Active CA2901696C (en) | 2013-02-19 | 2014-02-18 | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160002185A1 (enExample) |
| EP (1) | EP2958902B1 (enExample) |
| JP (1) | JP6417338B2 (enExample) |
| AU (1) | AU2014219075C1 (enExample) |
| CA (1) | CA2901696C (enExample) |
| MX (1) | MX362896B (enExample) |
| WO (1) | WO2014130470A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物 |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| JP6377123B2 (ja) | 2013-03-14 | 2018-08-22 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物 |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| MX378969B (es) | 2013-11-11 | 2025-03-11 | Amgen Inc | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. |
| PL3458101T3 (pl) | 2016-05-20 | 2021-05-31 | F. Hoffmann-La Roche Ag | Koniugaty PROTAC-przeciwciało i sposoby ich stosowania |
| WO2019166629A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3246148A1 (de) * | 1982-12-14 | 1984-06-14 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| AU2005295441B2 (en) | 2004-10-18 | 2009-04-23 | Amgen, Inc. | Thiadiazole compounds and methods of use |
| WO2007084391A2 (en) | 2006-01-18 | 2007-07-26 | Amgen Inc. | Thiazole compounds as protein kinase b ( pkb) inhibitors |
| US7705018B2 (en) | 2007-03-23 | 2010-04-27 | Amgen Inc. | Substituted quinolines and their uses in treatment of inflammatory and related conditions |
| US7919498B2 (en) | 2007-03-23 | 2011-04-05 | Amgen Inc. | Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors |
| AU2008231304B2 (en) | 2007-03-23 | 2011-05-12 | Amgen Inc. | Heterocyclic compounds and their uses |
| CA2692720A1 (en) * | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k |
| US7897619B2 (en) | 2007-07-17 | 2011-03-01 | Amgen Inc. | Heterocyclic modulators of PKB |
| AU2008276512A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of PKB |
| TW200911798A (en) | 2007-08-02 | 2009-03-16 | Amgen Inc | PI3 kinase modulators and methods of use |
| CA2710194C (en) | 2007-12-19 | 2014-04-22 | Amgen Inc. | Inhibitors of p13 kinase |
| US8841312B2 (en) | 2007-12-19 | 2014-09-23 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| JP5530422B2 (ja) | 2008-04-07 | 2014-06-25 | アムジエン・インコーポレーテツド | 細胞周期阻害薬としてのｇｅｍ−二置換およびスピロ環式アミノピリジン／ピリミジン |
| US8415376B2 (en) | 2008-05-30 | 2013-04-09 | Amgen Inc. | Inhibitors of PI3 kinase |
| US20110263647A1 (en) | 2009-01-15 | 2011-10-27 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
| WO2010096314A1 (en) | 2009-02-18 | 2010-08-26 | Amgen Inc. | INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS |
| MX2011009796A (es) | 2009-03-20 | 2011-12-14 | Amgen Inc | Inhibidores de la cinasa pi3. |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| EP2430013B1 (en) | 2009-05-13 | 2014-10-15 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| EA201270013A1 (ru) | 2009-06-25 | 2012-06-29 | Амген Инк. | Гетероциклические соединения и их применение |
| MX2011013667A (es) | 2009-06-25 | 2012-03-06 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| WO2010151791A1 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses |
| WO2010151735A2 (en) | 2009-06-25 | 2010-12-29 | Amgen Inc. | Heterocyclic compounds and their uses |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| JP6093770B2 (ja) * | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物 |
-
2014
- 2014-02-18 CA CA2901696A patent/CA2901696C/en active Active
- 2014-02-18 US US14/768,529 patent/US20160002185A1/en not_active Abandoned
- 2014-02-18 EP EP14708410.7A patent/EP2958902B1/en active Active
- 2014-02-18 MX MX2015010619A patent/MX362896B/es active IP Right Grant
- 2014-02-18 AU AU2014219075A patent/AU2014219075C1/en active Active
- 2014-02-18 WO PCT/US2014/016971 patent/WO2014130470A1/en not_active Ceased
- 2014-02-18 JP JP2015558205A patent/JP6417338B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016509029A (ja) | 2016-03-24 |
| EP2958902B1 (en) | 2017-11-15 |
| MX2015010619A (es) | 2016-04-19 |
| JP6417338B2 (ja) | 2018-11-07 |
| US20160002185A1 (en) | 2016-01-07 |
| EP2958902A1 (en) | 2015-12-30 |
| CA2901696A1 (en) | 2014-08-28 |
| MX362896B (es) | 2019-02-22 |
| AU2014219075A1 (en) | 2015-08-27 |
| AU2014219075C1 (en) | 2018-09-06 |
| AU2014219075B2 (en) | 2018-03-01 |
| WO2014130470A1 (en) | 2014-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2901696C (en) | Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer | |
| CA2850166C (en) | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer | |
| CA2906538C (en) | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer | |
| CA2799972C (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| AU2020267169B2 (en) | Processes of making and crystalline forms of a MDM2 inhibitor | |
| CA2902856C (en) | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer | |
| US8901307B2 (en) | Chemical compounds 251 | |
| US11407721B2 (en) | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer | |
| WO2014035872A1 (en) | Tricyclic alkynes that interact with glucokinase regulatory protein | |
| HK1231864A1 (en) | Heterocyclic compounds as nav channel inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190215 |